Telix Pharmaceuticals Limited

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 10:02:41 2024-04-30 pm EDT			5-day change	1st Jan Change
14.78 ^AUD	-1.79%		+3.36%	+46.63%

Apr. 30	Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	MT
Apr. 18	Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy	MT

Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024

April 17, 2024 at 03:05 am EDT

Telix Pharmaceuticals Limited reaffirmed revenue guidance for the year 2024. For full year revenue expected to be in the range of
USD 445 million to USD 465 million (AUD 675 million to AUD 705 million at current exchange rates), representing an approximate 35-40% increase versus 2023.

Latest news about Telix Pharmaceuticals Limited

Bell Potter Downgrades Telix Pharmaceuticals to Hold from Buy, Price Target is AU$14.50	Apr. 29	MT
Jarden Adjusts Telix Pharmaceuticals Price Target to AU$13.52 from AU$13.27, Keeps at Buy	Apr. 17	MT
Telix Pharmaceuticals Limited Reports Unaudited Revenue Results for the First Quarter Ended 31 March 2024	Apr. 17	CI
Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024	Apr. 17	CI
Telix Pharmaceuticals Logs Nearly $115 Million Revenue in Q1	Apr. 17	MT
Telix Pharmaceuticals Secures US FDA Fast-Track Designation for Brain Cancer Imaging Product	Apr. 15	MT
Telix Pharmaceuticals Limited Announces FDA Fast Track Designation for TLX101-CDx	Apr. 15	CI
Telix Pharmaceuticals Completes Acquisition of Canadian Firm ARTMS	Apr. 11	MT
Telix Pharmaceuticals Limited completed the acquisition of ARTMS, INC.	Apr. 10	CI
Telix Pharmaceuticals Completes Acquisition of IsoTherapeutics Group	Apr. 08	MT
Telix Pharmaceuticals Limited completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million.	Apr. 08	CI
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent	Mar. 25	CI
Telix Pharmaceuticals Appoints Group COO; Shares Down 4%	Mar. 11	MT
Telix Pharmaceuticals to Buy Canadian Radioisotope Production Firm ARTMS	Mar. 04	MT
Telix Pharmaceuticals Limited signed an agreement to acquire ARTMS, INC. for approximately $84 million.	Mar. 03	CI
Telix Pharmaceuticals Jumps 7% on IsoTherapeutics Group Acquisition Deal	Feb. 26	MT
Telix Pharmaceuticals Limited entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million.	Feb. 25	CI
Transcript : Telix Pharmaceuticals Limited, 2023 Earnings Call, Feb 23, 2024	Feb. 22
Telix Pharmaceuticals Posts 214% Surge in FY23 Revenue; Returns to Profit	Feb. 22	MT
Telix Pharmaceuticals Limited Provides Earnings Guidance for Full Year Revenue 2024	Feb. 22	CI
Telix Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Telix Pharmaceuticals to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform	Feb. 07	MT
Australia shares led higher by Financials; US inflation in focus	Jan. 10	RE
Transcript : Telix Pharmaceuticals Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 03:00 PM	Jan. 09
Telix Pharmaceuticals Limited Announces Unaudited Revenue Results for the Fourth Quarter and Full Fiscal Year 2023	Jan. 08	CI

Chart Telix Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Annual General Meeting

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Telix Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.05 AUD

Average target price

15.29 AUD

Spread / Average Target

+1.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TELIX PHARMACEUTICALS LIMITED	+46.63%	3.36B
IQVIA HOLDINGS INC.	+0.17%	42.86B
MODERNA, INC.	+10.92%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.23%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.63B
MEDPACE HOLDINGS, INC.	+26.69%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.92B
UNITED THERAPEUTICS CORPORATION	+6.57%	11.21B

Other Biotechnology & Medical Research